NASDAQ:AGTC - Applied Genetic Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.15 -0.05 (-1.19 %)
(As of 07/20/2018 08:35 AM ET)
Previous Close$4.20
Today's Range$4.05 - $4.30
52-Week Range$3.25 - $5.75
Volume101,109 shs
Average Volume100,116 shs
Market Capitalization$76.06 million
P/E Ratio207.50
Dividend YieldN/A
Applied Genetic Technologies logoApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.

Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio6.61
Quick Ratio6.61


Trailing P/E Ratio207.50
Forward P/E Ratio-3.99
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.47 million
Price / Sales1.90
Cash Flow$0.0720 per share
Price / Cash57.67
Book Value$6.38 per share
Price / Book0.65


EPS (Most Recent Fiscal Year)$0.02
Net Income$400,000.00
Net Margins-65.96%
Return on Equity-16.00%
Return on Assets-13.16%


Outstanding Shares18,110,000
Market Cap$76.06

Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Corp (NASDAQ:AGTC) issued its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.04. The biotechnology company had revenue of $3.60 million for the quarter, compared to analyst estimates of $6.41 million. Applied Genetic Technologies had a negative return on equity of 16.00% and a negative net margin of 65.96%. View Applied Genetic Technologies' Earnings History.

When is Applied Genetic Technologies' next earnings date?

Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, September, 12th 2018. View Earnings Estimates for Applied Genetic Technologies.

What price target have analysts set for AGTC?

5 brokers have issued 1 year price targets for Applied Genetic Technologies' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Applied Genetic Technologies' stock price to reach $9.00 in the next year. This suggests a possible upside of 116.9% from the stock's current price. View Analyst Ratings for Applied Genetic Technologies.

What is the consensus analysts' recommendation for Applied Genetic Technologies?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Applied Genetic Technologies stock?

Here are some recent quotes from research analysts about Applied Genetic Technologies stock:
  • 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (7/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy." (10/6/2017)

Who are some of Applied Genetic Technologies' key competitors?

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the folowing people:
  • Ms. Susan B. Washer, Pres, CEO & Director (Age 57)
  • Dr. Mark S. Shearman Ph.D., Chief Scientific Officer (Age 58)
  • Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 62)
  • Dr. Nicholas Muzyczka, Co-Founder
  • Dr. Barry J. Byrne, Co-Founder

Has Applied Genetic Technologies been receiving favorable news coverage?

Media coverage about AGTC stock has trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Applied Genetic Technologies earned a media sentiment score of 0.24 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.11 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Municipal Employees Retirement System of Michigan (1.33%). Company insiders that own Applied Genetic Technologies stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies.

Which major investors are selling Applied Genetic Technologies stock?

AGTC stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Applied Genetic Technologies.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $4.15.

How big of a company is Applied Genetic Technologies?

Applied Genetic Technologies has a market capitalization of $76.06 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.

MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.